Article
Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with PIK3CA-Mutant Cancers.
Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Jan 2021
Jhaveri Komal, Chang Matthew T, Juric Dejan, Saura Cristina, Gambardella Valentina, Melnyk Anton, Patel Manish R, Ribrag Vincent, Ma Cynthia X, Aljumaily Raid, Bedard Philippe L, Sachdev Jasgit C, Dunn Lara, Won Helen, Bond John, Jones Surai, Savage Heidi M, Scaltriti Maurizio, Wilson Timothy R, Wei Michael C, Hyman David M
Abstract excerpt
PURPOSE: Somatic mutations in phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA), which encodes the p110α catalytic subunit of PI3K, are found in multiple human cancers. While recurrent mutations in PIK3CA helical, regulatory, and kinase domains lead to constitutive PI3K pathway activation, other mutations remain uncharacterized. To further evaluate their clinical actionability, we...
Topics
Join the communities discussing this publication.